Although the world has returned to a state of relative normalcy, SARS-CoV-2 infections continue to persist worldwide, and immune evasive variants continue to emerge. Monoclonal antibodies (mAbs) are often first in line therapy for SARS-CoV-2 infections, but most have lost utility against the Omicron variant and its subvariants. One mAb cocktail, Evusheld,...

­Vaccines are an essential tool in preventing and controlling many diseases. Most approved vaccines are inactivated or live attenuated type, however, alternative platforms like mRNA and virus-like particles (VLPs) are being increasingly explored and approved because they generate potent immune responses with great safety profiles. VLPs are particularly...

Chikungunya virus (CHIKV) is a mosquito‐borne alphavirus, characterized by fever and severe joint pain. The joint pain is often debilitating and can vary in duration, sometimes lasting for years. There are currently no vaccines or therapeutic treatments for CHIKV, instead symptom relief is the primary focus with administration of bed rest, antipyretics/analgesics...